Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma
暂无分享,去创建一个
Huaqing Zhao | John M Maris | K. Cole | J. Maris | J. Christensen | J. Plegaria | Y. Mossé | A. Wood | M. Lemmon | E. Carpenter | Huaqing Zhao | S. Bresler | Mark A Lemmon | Erica L Carpenter | James G Christensen | Joshua Courtright | Scott C Bresler | Andrew C Wood | Elizabeth A Haglund | Lili T Belcastro | Jefferson S Plegaria | Kristina Cole | Yana Toporovskaya | Yaël P Mossé | Lili T. Belcastro | L. Belcastro | E. Haglund | J. Courtright | Y. Toporovskaya
[1] L. Tanoue,et al. Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer , 2012 .
[2] O. Delattre,et al. The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking , 2011, Oncogene.
[3] Ryohei Katayama,et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK , 2011, Proceedings of the National Academy of Sciences.
[4] H. Carén,et al. Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy. , 2011, Cancer research.
[5] M. Xing,et al. Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. , 2011, Cancer research.
[6] Wei Zheng,et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. , 2010, Cancer research.
[7] Young Lim Choi,et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. , 2010, The New England journal of medicine.
[8] Glen Spraggon,et al. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain. , 2010, The Biochemical journal.
[9] Andrea Lombardi Borgia,et al. Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors. , 2010, Biochemistry.
[10] M. Eck,et al. Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer. , 2010, Biochimica et biophysica acta.
[11] Vermeulen,et al. Clinical Cancer esearch an Cancer Biology a-analysis of Neuroblastomas Reveals a Skewed ALK R ation Spectrum in Tumors with MYCN Amplification , 2010 .
[12] John R. Engen,et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M , 2009, Nature.
[13] P. Sabbatini,et al. GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers , 2009, Molecular Cancer Therapeutics.
[14] R. Palmer,et al. Anaplastic lymphoma kinase: signalling in development and disease , 2009, The Biochemical journal.
[15] H. Carén,et al. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. , 2008, The Biochemical journal.
[16] S. Grupp,et al. Late effects in survivors of tandem peripheral blood stem cell transplant for high‐risk neuroblastoma , 2008, Pediatric blood & cancer.
[17] John M. Maris,et al. Identification of ALK as a major familial neuroblastoma predisposition gene , 2008, Nature.
[18] Gudrun Schleiermacher,et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma , 2008, Nature.
[19] S. Ogawa,et al. Oncogenic mutations of ALK kinase in neuroblastoma , 2008, Nature.
[20] D. Gary Gilliland,et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma , 2008, Nature.
[21] M. Meyerson,et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP , 2008, Proceedings of the National Academy of Sciences.
[22] Shinji Yamazaki,et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma , 2007, Molecular Cancer Therapeutics.
[23] H. Aburatani,et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.
[24] Daniel A. Haber,et al. Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.
[25] Stuart Thomson,et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. , 2006, Cancer research.
[26] John Kuriyan,et al. An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor , 2006, Cell.
[27] Cristina M Furdui,et al. Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction. , 2006, Molecular cell.
[28] H. Koerten,et al. Signalling in development and disease , 2006 .
[29] C. Créminon,et al. Activation and Inhibition of Anaplastic Lymphoma Kinase Receptor Tyrosine Kinase by Monoclonal Antibodies and Absence of Agonist Activity of Pleiotrophin* , 2005, Journal of Biological Chemistry.
[30] L. Scapozza,et al. Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity. , 2005, Biochemistry.
[31] R. Weis,et al. Template-directed assembly of receptor signaling complexes. , 2003, Biochemistry.
[32] S. Hubbard,et al. Crystal structure of the MuSK tyrosine kinase: insights into receptor autoregulation. , 2002, Structure.
[33] Stevan R. Hubbard,et al. Structure and autoregulation of the insulin-like growth factor 1 receptor kinase , 2001, Nature Structural Biology.
[34] C. Walsh,et al. Divalent ion effects and insights into the catalytic mechanism of protein tyrosine kinase Csk. , 1997, Biochemistry.
[35] T. Arakawa,et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system , 1997, Oncogene.
[36] D N Shapiro,et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.
[37] D N Shapiro,et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.
[38] E. Goldsmith,et al. Autophosphorylation activates the soluble cytoplasmic domain of the insulin receptor in an intermolecular reaction. , 1989, The Journal of biological chemistry.
[39] C E Koop,et al. Special pattern of widespread neuroblastoma with a favourable prognosis. , 1971, Lancet.
[40] K. Vonkaulla. LIVER IN REGULATION OF FIBRINOLYTIC ACTIVITY. , 1964, Lancet.
[41] V. Schramm,et al. Mn 2 +-binding properties of a recombinant protein-tyrosine kinase derived from the human insulin receptor ( conformational change / secondary structure / electron a ge resonance / drcular dichroism ) , 2022 .